Electroconvulsive Therapy (ECT)
ECT is indicated for persons with major depressive disorder experiencing severe symptoms, functional impairment, and have had a poor response to medication. It is also recommended for individuals who are refusing food and have become nutritionally compromised, unable to take antidepressant medications due to a medical condition, or identified as having a history of a positive response to ECT. It is found to be 80% to 90% effective in individuals with major depression. Medication-resistant persons show at least a 50% satisfactory response.
ECT is a procedure during which electricity briefly stimulates the brain causing a seizure. It is given under general anesthesia and medication. The anesthesia causes a loss of sensation and consciousness and the medication relaxes the muscles to eliminate body movement during the procedure. The duration of the seizure is typically 15 to 25 seconds. The electrical stimulation is believed to cause changes in the chemistry of the brain that are beneficial to the depressed individual.
Although identified as a generally safe treatment, ECT does have side-effects. The chief side-effects are cognitive, including confusion and memory impairment. It is difficult to separate these side-effects from the actual depressive symptoms. They are typically resolved in a few weeks. The risks of mortality are not higher than those associated with anesthesia.
The course of treatment is individualized depending on the response to treatment. The person should reach full recovery or a plateau. Generally 6 to 12 treatments are required to achieve the desired result. The treatments are typically administered every other day. After ECT is complete, the individual should be maintained on antidepressant medication or lithium. Medication-resistant individuals may require maintenance ECT treatment.
St. John's wort
St. Johns wort is a plant product with antidepressant properties. It is not FDA approved, although studies continue. This results in a lack of preparation standards for ingredients, composition, and potency. Limited trials have indicated that it has greater benefit than placebo and is comparable to low-dose tricyclic medications for those with mild to moderate depression. However, the use of St. John's wort and MAOIs is not recommended. The safety of use with other antidepressants is unknown.